May 5, 2020

7:00 – 8:00 am  Registration and Continental Breakfast

8:00 – 8:15 am  Opening Remarks

Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting, previously Defined Health

8:15 – 9:00 am  Keynote:

   Speaker: Michael A Curran, PhD, Associate Professor, Dept. of Immunology
   Scientific Director, ORBIT Platform, The University of Texas MD Anderson Cancer Center, Department of Immunology, Division of Basic Sciences

9:00 – 10:15 am  Paradigm-shifting platforms I, IO: Taking IO to the next Level

   Moderator: Jeffrey M. Bockman, PhD, EVP, Oncology Practice Head, Cello Health BioConsulting

   Panelists:
   - Jacob Becraft, PhD, CEO, Co-founder, Strand Therapeutics
   - Frank Borriello, Founder & CEO, Alloplex Biotherapeutics Inc.
   - Mary Haak-Frendscho, President & CEO, Spotlight Therapeutics
   - Ulrik Nielsen, CEO, Tidal Therapeutics
   - Lini Pandite, MD, CMO, Shattuck Labs, Inc.
   - Laurent Levy, PhD, CEO Nanobiotix
   - Sijme Zeilemaker, COO, Immunicum

10:15 – 10:30 am  Networking Break

10:30 – 11:45 am  Paradigm-shifting platforms II, Non-IO: Targeting Better, Targeting the Intractable

   Moderator: James T. Lee, PhD, Associate Principal, Oncology Lead, Cello Health BioConsulting, previously Defined Health

   Panelists:
   - Robert A Copeland, PhD, President & CSO, Accent Therapeutics, Inc.
   - Christopher C. LeMasters, CBO, Mirati Therapeutics, Inc.
   - Vicky Richon, PhD, President & CEO, Ribon Therapeutics
   - Mark Rolfe, PhD, SVP, BMS
   - Tingting Zhang-Kharas, PhD, Oncology External Innovation Advisor Eli Lilly and Company

11:45 – 12:45 pm  Networking Luncheon & Keynote:
Investing into Oncology: Who, What and Where?

Moderator: Mark Simon, Managing Director, Torreya

Panelists:
- Michael Gladstone, Principal, Atlas Venture
- Michael G. King Jr., Entrepreneur in Residence, Fortress Biotech Inc.
- Christoph Lengauer, PhD, MBA, Partner, Third Rock Ventures
- Vanessa Lucey, PhD, MBA, Director, CRI Venture Fund & Clinical Accelerator, Cancer Research Institute
- Bibhash Mukhopadhyay, PhD, Principal, NEA
- Michal Silverberg, MBA, Novartis Venture Funds
- Michele Cleary, PhD, CEO, The Mark Foundation for Cancer Research

Networking Break

Vaccines: From Paleo to Neo, Cancer Vaccines in the New Age of IO

Moderator: Jeffrey M. Bockman, PhD, EVP, and Serom Lee, PhD, Consultant, Cello Health BioConsulting

Panelists:
- Andrew Allen, MD, PhD, President & CEO, Gritstone Oncology, Inc.
- Nina Bhardwaj, MD, PhD, Director of Cancer Immunotherapy, Professor of Medicine, The Tisch Cancer Institute, Icahn School of Medicine at Mt Sinai
- Chip Clark, President & CEO, Genocea Biosciences
- Erik Digman Wiklund, PhD, CBO, Targovax
- Paisley Myers, PhD, Senior Scientist, Agenus Inc.
- Mai-Britt Zocca, PhD, CEO, IO Biotech
- Gad Berdugo, CEO, EpiVax Oncology, Inc.

Inflecting Value in Early Stage Biotech: Linking Proof of Relevance to Pricing & Reimbursement

Moderator: Ed Saltzman, Executive Chairman, Cello Health BioConsulting

Panelists:
- Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Anna Kaltenboeck, Program Director & Senior Health Economist Department of Epidemiology and Biostatistics, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Robert Glassman, MD, Vice-Chairman, Health Care Group, Credit Suisse

Cancer Progress 2020 Reception
May 6, 2020

7:00 – 8:00 am  Registration and Continental Breakfast

8:00 – 8:15 am  Opening Remarks: Review of Day 1

8:15 – 9:30 am  Next Wave of Diagnostics, Including Precision IO: Early and Smarter, the Better to Cure

**Moderator:** Brian Leyland Jones, MBBS, PhD, VP, Avera Cancer Institute Center for Precision Oncology & Dept. of Molecular & Experimental Medicine, Avera Cancer Institute

**Panelists:**
- David Fabrizio, VP, Product Development, Foundation Medicine, Inc
- Colin Hill, CEO, Co-founder & Chairman, GNS Healthcare, Inc.
- Christoph Lengauer, PhD, MBA, Chief Innovation Officer, Thrive Earlier Detection Corp.
- Jimmy Lin, MD, PhD, MHS, CSO, Freenome

Advanced Therapeutics

9:30- 10:45 am  Antigen/platform pairings (“Forget Wine and Cheese...Get this Right and Your Valuation Takes Flight”)

**Moderator:** Joel S. Sandler, PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**
- Stephen Eck, MD, PhD, Chief Medical Officer, Immatics US
- Dora Mitchell, PhD, VP Business Development, Carisma Therapeutics Inc.
- Filippo Petti, CEO, Celyad
- Henry Rath, CBO, TScan Therapeutics
- Ian Somaiya, CFO, TCR2 Therapeutics Inc.
- Sharon Benzeno, PhD, MBA, SVP Drug Discovery, Adaptive Biotechnologies Corp
- Travis Quigley, VP, Clinical Development, Arcellx, Inc.

10:45 – 11:00 am  Networking Break
11:00 – 12:15 pm  
State of the union for off-the-shelf ("In an ‘Allo or Bust’ Market, What’s Rising to the Top of the Shelf?")

**Moderator:** Michael C. Rice, MS, MBA, Principal, Cello Health BioConsulting, previously Defined Health

**Panelists:**
- Robert Ang, MD, MBA, CEO, Vor BioPharma Inc.
- Jim Beitel, MD, PhD, SVP, Corporate Development, Fate Therapeutics Inc
- Thomas J. Farrell, President & CEO, Artiva Biotherapeutics or Peter Flynn, Chief Technology Officer, Artiva Biotherapeutics
- Maksim Mamonkin PhD, Assistant Professor, Pathology & Immunology Center for Cell and Gene Therapy, Baylor College of Medicine
- Julia Chapman, Director, Alliance Management, Precision BioSciences
- Arthur Stril, Vice President, Corporate Development, Cellectis

12:15 – 12:45 pm  
Fireside Chat with Samit Hirawat, MD, CMO, Bristol-Myers Squibb

12:45 - 1:30 pm  
Networking Lunch

1:30 – 2:45 pm  
What are investors and partners looking for today ("How to Stand Out/Inflect Value in a Frothy Vat of Cells")

**Moderator:** John Bishai, VP, Healthcare Investment Banking, Wells Fargo Securities

**Panelists:**
- John Delyani, PhD, MBA, VP Corporate Development, Tmunity Therapeutics Inc
- Michael Kalos, PhD, EVP and Head of R&D, Arsenal Biosciences
- Michael G. King Jr., Entrepreneur in Residence, Fortress Biotech Inc.
- Mark Simon, Managing Director, Torreya
- Sharon Rooney-Mayer, Executive Director, Global Disease Strategy Lead Cell and Gene Therapies, Novartis Oncology
- Lee Greenberger, MD, PhD, SVP & CSO, Leukemia & Lymphoma Society
- Stanley Frankel, MD, SVP, Cellular Therapy, Celgene

2:45 - 3:00 pm  
Networking Break

3:00 – 4:15 pm  
Strategic Considerations in ACT Manufacturing ("From Here to There, and Back Again")

**Moderator:** Steven A. Feldman, Ph.D. Director, Manufacturing and Process Development, Center for Cancer Cell Therapy, Stanford Cancer Institute/ Stanford School of Medicine

**Panelists:**
- Eytan Abraham, Head of Personalized Medicine, Lonza Pharma & Biotech
4:15 – 5:30 pm  Oncology Modalities Facing Off: Room for Many or One to Rule them All?

Moderator: Cello Health BioConsulting TBD

Panelists:
- Llew Keltner, CEO, EPISTAT
- Vanessa Lucey, PhD, MBA, Director, CRI Venture Fund & Clinical Accelerator, Cancer Research Institute
- Michael Kalos, PhD, EVP and Head of R&D, Arsenal Biosciences
- Michael DeRidder, VP, Medicine Commercialization Leader, Oncology Cell Therapy, GSK
- Jason Litten, MD, CMO, Artiva Biotherapeutics

5:30 pm  Cancer Progress 2020 Conference Concludes